Over the next five years, Geistlich Pharma AG, a leading company in tissue regeneration, and Humanitas University, a prominent international higher education institution dedicated to clinical and translational research, will coordinate the MEFISTO project with the help of SCIPROM Sàrl. The data for the meniscus implant design will be prepared by Universiteit Antwerpen and Universitätsklinikum Regensburg. Together with Universitair Medisch Centrum Utrecht, they will perform pre-clincal evaluation which includes establishing in-vitro testing protocols to assess implant performance as well as selecting appropriate in-vivo animal models to evaluate effectiveness of the different implants. Consiglio Nazionale delle Ricerche Napoli will be responsible for design, preparation and characterization of bio-ink and scaffold. Universidad de Santiago de Compostela will provide their expertise in nanoparticles, growth factors and anti-inflammatory molecules loading and incorporation in the scaffold, and Tissue Click Ltd. will lead the functionalisation and scaffold characterisation by contributing their peptide technology. Cell culture conditions, evaluation of cell migration and cell viability will be performed by Établissement français du sang. A non-resorbable meniscus implant with drug delivery capabilities will be developed by Active Implants. The MEFISTO exploitation strategy will be developed through interaction with stakeholders, supported by an assessment of Key Performance Indicators delivered by Orthokey Italia S.r.l. and a health economic analysis performed by AiM GmbH. The health economic analysis includes the review of data from existing treatment options, design and programming of a health economic model and running the analysis.